Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

MLA

Bass, Ann D., et al. “Alemtuzumab Outcomes by Age: Post Hoc Analysis from the Randomized CARE-MS Studies over 8 Years.” Multiple Sclerosis and Related Disorders, vol. 49, no. 1, Apr. 2021. EBSCOhost, https://doi.org/10.1016/j.msard.2020.102717.

APA

Bass, A. D., Arroyo, R., Boster, A. L., Boyko, A. N., Eichau, S., Ionete, C., Limmroth, V., Navas, C., Pelletier, D., Pozzilli, C., Ravenscroft, J., Sousa, L., Tintoré, M., Uitdehaag, B. M. J., Baker, D. P., Daizadeh, N., Choudhry, Z., & Rog, D. (2021). Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders, 49(1). https://doi.org/10.1016/j.msard.2020.102717

Chicago

Bass, Ann D., Rafael Arroyo, Aaron L. Boster, Alexey N. Boyko, Sara Eichau, Carolina Ionete, Volker Limmroth, et al. 2021. “Alemtuzumab Outcomes by Age: Post Hoc Analysis from the Randomized CARE-MS Studies over 8 Years.” Multiple Sclerosis and Related Disorders 49 (1). doi:10.1016/j.msard.2020.102717.